N-Methyl-PPPA, or N-methyl-3-phenoxy-3-phenylpropan-1-amine, is a serotonin-norepinephrine reuptake inhibitor (SNRI) which was developed by Eli Lilly from diphenhydramine in the early 1970s while in search of new antidepressants, but was never marketed.[1][2][3] It is closely related structurally to fluoxetine, atomoxetine, and nisoxetine.[1][2][3]
Clinical data | |
---|---|
Other names | Detrifluoromethylfluoxetine |
ATC code |
|
Identifiers | |
| |
ChemSpider |
|
Chemical and physical data | |
Formula | C16H19NO |
Molar mass | 241.334 g·mol−1 |
3D model (JSmol) |
|
| |
|